Angiodynamics (ANGO) Liabilities and Shareholders Equity (2011 - 2026)

Angiodynamics has reported Liabilities and Shareholders Equity for 16 years, with the latest figure at $260.7 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 8.67% year-over-year to $260.7 million; the trailing twelve-month figure through Feb 2026 stood at $1.1 billion (down 9.44% YoY), and the FY2025 full-year result was $280.1 million, down 11.81% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $260.7 million, down from $269.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $558.2 million in Q4 2022, with the low at $260.7 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $404.1 million across 5 years, with a median of $324.8 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity increased 0.74% — and 2024, when it plunged 41.65%.
• Angiodynamics' Liabilities and Shareholders Equity stood at $558.2 million in 2022, then decreased by 10.49% to $499.6 million in 2023, then sank by 41.65% to $291.6 million in 2024, then fell by 7.5% to $269.7 million in 2025, then slipped by 3.34% to $260.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $260.7 million (Q1 2026), $269.7 million (Q4 2025), and $265.6 million (Q3 2025), per Business Quant data.